| Serial Number | 79348442 |
| Word Mark | BI-CYGNI |
| Filing Date | Tuesday, February 22, 2022 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, December 19, 2023 |
| Registration Number | 7245067 |
| Registration Date | Tuesday, December 19, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 3, 2023 |
| Goods and Services | Antibodies for medical purposes; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-infective antibiotics; anti-infective preparations; anti-infectives; anti-inflammatories; antiparasitic preparations; anti-viral agents; biological adjuvants for medical purposes; biological preparations for medical purposes, namely for the treatment of cancer; biological preparations for the treatment of cancer; biological preparations for veterinary purposes; biological diagnostic reagents for medical use; biological diagnostic reagents for veterinary use; biological tissue cultures for medical purposes; biopharmaceutical preparations for the treatment of cancer; biotechnological preparations for medical use for the treatment of cancer; blood components in the nature of blood protein fractions, blood cellular fractions, blood plasma and cord blood for medical purposes; cardiovascular pharmaceutical preparations; cardiovascular preparations; cells for medical use; cellular function activating agents for medical purposes; chemical adjuvants for medical purposes; chemical preparations for medical purposes, namely for prevention or treatment of cancer; chemical preparations for pesticidal purposes, namely, pesticides; chemical preparations for pharmaceutical purposes namely for prevention or treatment of cancer; chemical preparations for testing blood for medical purposes; chemical reagents for medical use; chemical preparations for pharmaceutical use, namely for prevention or treatment of cancer; chemotherapeutics; clinical diagnostic reagents for medical use; clinical medical reagents; pharmaceutical compounds for treating cancer; pharmaceutical compounds for treating correlated pulmonary syndromes; pharmaceutical compounds for treating respiratory diseases; cord blood for medical purposes; culture media for use in treatment of cancer for medical use; cultures of microorganisms and mammalian cultures for medical use; cytostatic drugs for medical purposes; cytostatics for medical purposes; cytostatics for pharmaceutical purposes; diagnostic agents for medical use; diagnostic agents for pharmaceutical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical use; diagnostic preparations and materials in the nature of cancer diagnostics for medical purposes; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic reagents for medical use; diagnostic reagents for medicinal use; diagnostic substances for medical use; diagnostic testing materials in the natural of cancer diagnostics for medical use; drugs for medical purposes, namely cancer treatment; haemostatic preparations in the nature of medical haemostatic paste, haemostatic pencils; homeopathic medicines in the nature of pharmaceuticals for use in the treatment of cancer; immunomodulators; immunostimulants; immunosuppressants for use following transplantation in the case of graft rejection; immunotherapeutic agents for bacterial infections; in vitro diagnostic preparations for medical use; living cells for medical use; living cells for veterinary use; medicines, namely, medicines for cancer disorders; medicines for human purposes, namely, cancer medicines; medicines for intestinal disorders; medicines for the treatment of gastrointestinal diseases; medicines for treating intestinal disorders; pain relief preparations in the nature of pain relief medication; pharmaceutical compositions, namely, preparations for the treatment of cancer; pharmaceutical drugs, namely, preparations for the treatment of cancer; pharmaceutical preparations, namely, preparations for the treatment of cancer; pharmaceutical preparations and substances, namely, preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for use in gynecology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in the field of anesthesia; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human use, namely, preparations for the treatment of cancer; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for medical purposes, namely, preparations for the treatment of cancer; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of allergies; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of diseases of the metabolic system; pharmaceutical preparations for the prevention of diseases of the musculo-skeletal system; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention of disorders caused by bacteria; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the prevention of disorders of the endocrine system; pharmaceutical preparations for the prevention of disorders of the genitourinary system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for the prevention of disorders of the musculo-skeletal system; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of disorders of the respiratory system; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of ocular diseases; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of diseases caused by bacteria; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the genitourinary system; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of diseases of the musculo-skeletal system; pharmaceutical preparations for the treatment of disorders caused by bacteria; pharmaceutical preparations for the treatment of disorders of the endocrine system; pharmaceutical preparations for the treatment of disorders of the genitourinary system; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of esophagitis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating digestive system disorders; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for treating rheumatological diseases; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for treating skeletal diseases; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for treating the symptoms of radiation sickness; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for use in urology; pharmaceutical preparations for veterinary use for the prevention and treatment of cancer; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals and natural remedies for the prevention and treatment of cancer; pharmacological preparations for skin care; preparations for the treatment of asthma; radioactive substances for medical purposes; radio-isotope markers for therapeutic or diagnostic use; radiological contrast substances for medical purposes; radiopharmaceutical products, namely, pharmaceutical products for the prevention and treatment of cancer; clinical medical reagents for analytical purposes; clinical reagents for veterinary or medicalanalytical purposes; clinical medical reagents for in-vitro laboratory use; clinical veterinary reagents for in-vitro laboratory use; clinical reagents for medical use; clinical medical reagents for use in diagnostic tests; clinical veterinary reagents for use in diagnostic tests; reconstituted cells for clinical treatments for skin care; reconstituted cells for medical treatments for skin care; tissue-regenerative pharmaceutical preparations; tissues for medical use in the nature of biological tissue grafts and human allograft tissue |
| Translation of Words in Mark | The wording CYGNI has no meaning in a foreign language. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 052, 051, 005, 018, 006, 044, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 2, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | BIVICTRIX LIMITED |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | BIVICTRIX LIMITED |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | BIVICTRIX LIMITED |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, March 28, 2024 | FINAL DISPOSITION NOTICE SENT TO IB |
| Thursday, March 28, 2024 | FINAL DISPOSITION PROCESSED |
| Tuesday, March 19, 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, December 19, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, December 19, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, October 4, 2023 | NOTIFICATION PROCESSED BY IB |
| Tuesday, October 3, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 3, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, September 13, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, September 13, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, September 13, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, August 25, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, August 25, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Friday, August 25, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, August 25, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Friday, August 25, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, August 8, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, August 7, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, August 7, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, February 28, 2023 | REFUSAL PROCESSED BY IB |
| Wednesday, February 8, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, February 7, 2023 | REFUSAL PROCESSED BY MPU |
| Tuesday, December 13, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, December 12, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, December 6, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, September 6, 2022 | APPLICATION FILING RECEIPT MAILED |
| Friday, September 2, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, September 1, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |